A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Other illness

• Any surgical and/or medical condition, which in the opinion of the treating physician, may place the participant at higher risk of his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.

Lab values

• Participants who have previous exposure to inclisiran sodium.

Other

• Pregnant or nursing (lactating) women.

• Male and female Indian participants aged ≥18 years or older.
• Participants for whom the treating physician prescribes treatment with inclisiran sodium in adherence with the India PI i.e., patients who are diagnosed with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:
  • in combination with a statin or statin with other LLTs in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other LLTs in patients who are intolerant to statins or for whom a statin is contraindicated.
• Participants on LLTs should be on a stable dose for ≥30 days before the first dose administration of the study treatment.